More Videos
SPECIAL REPORT
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
- Predictions 2010: Consumers
- Who Were the Biggest Winners And Losers This Year?
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Cramer: Watch Tech Stocks on Wednesday – Here’s Why
- Stocks Likely Don't Need Santa to Keep Rally Going
- Larry Kudlow's Open Letter to Tiger Woods
- Super Fantasy Christmas Gifts of 2009
- AIG Slashes US Debt Under Deal With New York Fed
- Seamstress Fined $5.7 Million for Insider Trading
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
This blog is an exception to the rule.
Yesterday, Vanda Pharmaceuticals had a market value of $28 million. That's way too small to mention on CNBC, here on the blog or even on Twitter.
But exceptions can be made when a company, even one that little, has real news.
Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt. I've gotta hand it to Adam Feuerstein at TheStreet.com on this one. He summarized the shock and awe of the situation when he wrote, "Hell froze over Wednesday night, right before a squadron of flying pigs took to the sky." Nice write, dude.
Vanda's M-O is to take other drug companies' trash in hopes of turning it into treasure. But the business model wasn't working out so well. The FDA had given Vanda what's called a "non-approvable" letter. That almost always means the drug is pretty much dead in the water. One major investor was pushing the company to fuggedaboutit.
VNDA became a penny stock.
I had once covered the company for awhile a couple or three years ago when it looked like it had something going on. We even had the CEO on live once or twice when I had to rehearse his name, Mihael Polymeropoulos, over and over and over to make sure I didn't mess it up on TV. "Polymeropoulos, Polymeropoulos, Polymeropoulos...."
Alright, I digress.
In this case, drug giant Novartis used to own the Fanapt, but unloaded it. NVS will still get a royalty on sales, but in an exclusive interview on CNBC's "Squawk on the Street" this morning, I asked the Swiss drugmaker's Chairman and CEO, Dr. Daniel Vasella (yes, he's an M.D. who specialized in psychosomatic illness), if he had seller's regret.
Is this a one-off or, to use an overworked term these days, a green shoot sprouting at the previously very stingy FDA? Natixis Bleichroeder analyst Corey Davis is one of the few analysts who was still covering the left-for-dead company. He writes in a research note to clients, "In one of the most surprising moves we've seen out of the FDA this year, the agency did a complete about face on Vanda's (Fanapt) and gave it outright approval. Perhaps the presence of a new commissioner is already having an effect." Davis, by the way, has to be a happy camper because he owns VNDA shares. And his firm makes a market in the stock.
I think it's too early to call this the dawn of a new day at the FDA. But when hell freezes over and pigs fly, who knows?
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes